Alectinib for treating patients with metastatic <i>ALK</i>-positive NSCLC: systematic review and network metanalysis-Reference-Cited by-同舟云学术

Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis

Published:2023-06 Issue:2 Volume:12 Page:
ISSN:1758-1966
Container-title:Lung Cancer Management
language:en
Short-container-title:Lung Cancer Management

Author:

Samacá-Samacá Daniel¹^ORCID,Prieto-Pinto Laura²^ORCID,Peréz Andrés Yepes³^ORCID,Valderrama Carolina¹,Hernández Fabián¹^ORCID

Affiliation:

1. IQVIA, Real World Insights, Bogotá, Colombia

2. Evidence Generation, Roche, Bogotá, Colombia

3. Oncology Unit, Centro Oncológico de Antioquia & Clínica de Oncología Astorga, Medellín, Colombia

Abstract

Aim: To compare the efficacy and safety of alectinib with other ALK inhibitors in treating patients with metastatic or locally advanced ALK-positive NSCLC. Methods: A systematic literature review was conducted up to November 2021. Network meta-analyses were performed using the frequentist method (random effects). GRADE evidence profile was conducted. Results: 13 RCTs were selected. For overall survival, alectinib was found to reduce the risk of death compared with crizotinib. In progression-free survival, alectinib reduced the risk of death or progression compared with crizotinib and ceritinib. Subgroup analysis by brain metastasis at baseline showed the superiority of alectinib over crizotinib and a similar effect compared with second-and third-generation inhibitors. Alectinib showed a good safety profile compared with the other ALK inhibitors.

Funder

F Hoffmann-La Roche

Publisher

Future Medicine Ltd

Subject

Modeling and Simulation

Link

https://www.futuremedicine.com/doi/pdf/10.2217/lmt-2022-0018

Reference53 articles.

1. Global Cancer Observatory: Lung Cancer Today (2022). https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf

2. Tasas de supervivencia del cáncer de pulmón (2021). www.cancer.org/es/cancer/cancer-de-pulmon/deteccion-diagnostico-clasificacion-por-etapas/tasas-de-supervivencia.html

3. American Society of Clinical Oncology. Cáncer de pulmón de células no pequeñas: estadísticas (2021). www.cancer.net/es/tipos-de-cancer/cancer-de-pulmon-de-celulas-no-pequenas/estadisticas

4. Molecular pathology of non-small cell lung cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ARE ALECTINIB-INDUCED MYALGIA AND ELEVATION CREATINE PHOSPHOKINASE PREDICTORS OF HIGH RECURRECCE-FREE SURVIVAL?;Art of Medicine;2024-06-29

2. First case report of a novel KIF13A-ALK fusion in a lung adenocarcinoma patient and response to alectinib with a 4-year follow-up;Frontiers in Genetics;2023-12-13